- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06503510
De rol van de interleukine-13-routes op pijn- en jeukgevoeligheid bij patiënten met atopische dermatitis en gezonde vrijwilligers (IL-13)
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the interleukin-13 is involved in inflammation and itch in atopic dermatitis by increasing the neuronal sensitivity to pruritogens. However, the physiological mechanisms by which IL-13 increases the itch sensitivity are unclear. The aim of this project is to use, for the first time in humans, the monoclonal antibody Lebrikizumab that inhibits IL-13 with high affinity as a novel experimental tool to modulate the IL-13 pathway and evaluate its role in the transmission and processing of itch and pain.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Silvia Lo Vecchio
- Telefoonnummer: 21397785
- E-mail: slv@hst.aau.dk
Studie Locaties
-
-
Aalborg
-
Gistrup, Aalborg, Denemarken, 9260
- Werving
- Aalborg University
-
Contact:
- Silvia Lo Vecchio, PhD
- Telefoonnummer: 21397785
- E-mail: slv@hst.aau.dk
-
Contact:
- Botilla Markussen
- Telefoonnummer: 20567502
- E-mail: bam@hst.aau.dk
-
Hoofdonderzoeker:
- Silvia Lo Vecchio, PhD
-
Onderonderzoeker:
- Botilla Markussen
-
Gistrup, Aalborg, Denemarken, 9260
- Actief, niet wervend
- CNAP
-
-
Denmark
-
Aalborg, Denmark, Denemarken, 9260
- Nog niet aan het werven
- Aalborg University
-
Contact:
- Silvia Lo Vecchio
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Healthy men and women
- 18-60 years
Exclusion Criteria:
- Pregnancy or lactation
- Drug addiction defined as any use of cannabis, opioids, or other drugs
- Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
- Moles, wounds, scars, or tattoos in the area to be treated or tested
- Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).
- Use of systemic and topical corticosteroids
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Acute or chronic pain
- Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
- Lack of ability to cooperate
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Lebrikizumab
The initial doses will be subcutaneous Lebrikizumab 500 mg (two 250 mg injections) at both week 0 (baseline) and week 2, followed by 250 mg administered subcutaneously at week 4. |
Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin. A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop. A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Superficial blood perfusion
Tijdsspanne: Baseline
|
Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
Baseline
|
|
Mechanically evoked itch (MEI)
Tijdsspanne: Baseline
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
Baseline
|
|
Measuring itch by computerized Visual Analog Scale Scoring
Tijdsspanne: 1 minute after every itch induction
|
The subjects will be asked to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable". |
1 minute after every itch induction
|
|
Measuring pain by computerized Visual Analog Scale Scoring
Tijdsspanne: 1 minute after every itch induction
|
The subjects will be asked to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". |
1 minute after every itch induction
|
|
Superficial blood perfusion
Tijdsspanne: 10 minute after every itch induction
|
Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
10 minute after every itch induction
|
|
Wheal reaction
Tijdsspanne: 10 minute after every itch induction
|
Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler. |
10 minute after every itch induction
|
|
Average pruritis and pain numerical rating scale (NRS)
Tijdsspanne: Baseline
|
The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days. |
Baseline
|
|
Skin peak pain numerical rating scale (SPP-NRS)
Tijdsspanne: Baseline
|
According to the SPP-NRS, the subject will be asked about "worst skin pain" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain) |
Baseline
|
|
Peak pruritus numerical rating scale (PP-NRS)
Tijdsspanne: Baseline
|
The subject will be asked about the "worst itch" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch) |
Baseline
|
|
Mechanically evoked itch (MEI)
Tijdsspanne: 10 minutes after every itch induction
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
10 minutes after every itch induction
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mechanical Pain Thresholds (MPT)
Tijdsspanne: Baseline
|
This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
Baseline
|
|
Mechanical Pain Sensitivity (MPS)
Tijdsspanne: Baseline
|
This test is conducted with the same pinprick set used to test the MPT. |
Baseline
|
|
Pressure Pain Thresholds (PPT)
Tijdsspanne: Baseline
|
Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm. |
Baseline
|
|
Cold Detection Thresholds (CDT)
Tijdsspanne: Baseliene
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseliene
|
|
Warm Detection Thresholds (WDT)
Tijdsspanne: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testingdevice |
Baseline
|
|
Cold Pain Thresholds (CPT)
Tijdsspanne: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
|
Heat Pain Thresholds (HPT)
Tijdsspanne: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
|
Pain to Supra-threshold Heat Stimuli (STHS)
Tijdsspanne: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Manifestaties van de huid
- Huidziektes
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Tekenen en symptomen
- Jeuk
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Azoles
- Biologische factoren
- Imidazolen
- Amines
- Ethylamines
- Autacoïden
- Ontstekingsmediatoren
- Biogene monoamine
- Biogene amines
- Histamine
- bovine adrenal medulla 8-22
Andere studie-ID-nummers
- N-20240029
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .